natgillin/translations-raw huggingface dataset:
NC
Z
How to store TAGRISSO
Shranjevanje zdravila TAGRISSO
Severe, life-threatening or fatal Interstitial Lung Disease (ILD) or ILD-like adverse reactions (e.g. pneumonitis) have been observed in patients treated with TAGRISSO in clinical studies.
V kliničnih študijah so pri bolnikih, zdravljenih z zdravilom TAGRISSO, opažali hude, življenjsko ogrožujoče in včasih smrtne primere intersticijske bolezni pljuč (IBP) ali neželenih učinkov, podobnih IBP (npr. pnevmonitisa).
TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets osimertinib
TAGRISSO 40 mg filmsko obložene tablete TAGRISSO 80 mg filmsko obložene tablete osimertinib
A HR< 1 favours TAGRISSO, an Odds ratio of >1 favours TAGRISSO Based on an interim analysis with 25% maturity a P-value < 0.0015 was required to achieve statistical significance ORR results by Blinded Independent Central Review (BICR) were consistent with those reported via investigator assessment; ORR by BICR assessment was 78% (95% CI:73, 83) on TAGRISSO and 70% (95% CI:65, 76) on EGFR TKI
Rezultati ORR po oceni slepljenega neodvisnega centralnega pregleda (BICR) so se skladali s tistimi po oceni raziskovalca; ORR po oceni BICR je bilo 78 % (95 % IZ: 73, 83) z zdravilom TAGRISSO in 70 (95 % IZ: 65, 76) s primerjalnim EGFR TKI.
At baseline, no differences in patient reported symptoms, function or HRQL were observed between TAGRISSO and EGFR TKI comparator (gefitinib or erlotinib) arms.
Izhodiščno med skupino z zdravilom TAGRISSO in skupino s primerjalnim EGFR TKI (gefitinib ali erlotinib) ni bilo razlik v simptomih, funkciji ali z zdravjem povezani kakovosti življenja po navedbi bolnikov.
Very common (35%) 4.1%
suha koža zelo pogosti (33 %)
TAGRISSO 80 mg film-coated tablets osimertinib
TAGRISSO 80 mg filmsko obložene tablete osimertinib
TAGRISSO 40 mg film-coated tablets osimertinib
TAGRISSO 40 mg filmsko obložene tablete osimertinib
Very common (54%) 1.6%
zmanjšano število trombocitov zelo pogosti (54 %)
Gastrointestinal effects
Učinki na prebavilih
Talk to your doctor, pharmacist or nurse before taking TAGRISSO if:
Pred začetkom jemanja zdravila TAGRISSO se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro:
Rare (0.02%)
Stevens-Johnsonov sindrom redki (0,02 %)
Dry skin
Okvara jeter
HRQL and physical functioning improvement analysis Patients on TAGRISSO had significantly greater chances of achieving a clinically meaningful improvement of greater than or equal to 10 points on the global health status and physical functioning of the EORTC-C30 questionnaire compared with chemotherapy during the study period Odds Ratio (OR) global health status: 2.11, (95% CI 1.24, 3.67, p=0.007); OR physical functioning 2.79 (95% CI 1.50, 5.46, p=0.002).
Razmerje obetov (RO) za splošno zdravstveno stanje: 2,11 (95 % IZ 1,24; 3,67; p = 0,007), RO za telesno delovanje 2,79 (95 % IZ 1,50; 5,46; p = 0,002).
Lusduna is used once a day at the same time each day.
Zdravilo Lusduna se uporablja enkrat na dan, vsak dan ob istem času.
Diabetes is a disease in which the level of blood sugar is high, either because the body cannot produce insulin (type 1 diabetes) or because the body does not make enough insulin or cannot use it effectively (type 2 diabetes).
Sladkorna bolezen je bolezen, pri kateri je raven sladkorja v krvi visoka, bodisi zato, ker telo ne more proizvajati insulina (sladkorna bolezen tipa 1), bodisi zato, ker telo ne proizvede dovolj insulina oziroma ga ne more učinkovito izrabljati (sladkorna bolezen tipa 2).
This means that Lusduna is highly similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU).
To pomeni, da je zelo podobno biološkemu zdravilu (t.i. „referenčnemu zdravilu“), ki je že odobreno v Evropski uniji (EU).
The full EPAR for Lusduna can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Lusduna je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Lusduna?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Lusduna?
This is a summary of the European public assessment report (EPAR) for Lusduna.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Lusduna.
It is given by injection under the skin in the belly, the thigh, or the upper arm.
Daje se z injekcijo pod kožo na trebuhu, stegnu ali nadlakti.
By controlling the level of blood glucose, the symptoms of diabetes are reduced and complications are avoided.
Z uravnavanje ravni glukoze v krvi se simptomi sladkorne bolezni zmanjšajo, zapletom pa se izognemo.
Because Lusduna is a biosimilar medicine, studies on effectiveness and safety were not needed as these have been well established for insulin glargine.
Ker je zdravilo Lusduna podobno biološko zdravilo, študije o učinkovitosti in varnosti niso bile potrebne, ker sta za insulin glargin dobro raziskani.
Lusduna is a medicine used in patients aged at least 2 years for the treatment of diabetes.
Lusduna je zdravilo, ki se uporablja pri bolnikih, starih vsaj dve leti, za zdravljenje sladkorne bolezni.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements for biosimilar medicines, Lusduna has been shown to have a comparable quality, safety and effectiveness to Lantus.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU glede podobnih bioloških zdravil dokazano, da je zdravilo Lusduna po kakovosti, varnosti in učinkovitosti primerljivo zdravilu Lantus.
In the second study, involving 531 patients with type 2 diabetes, the average reduction in HbA1c was from 8.3 to 7.2% with Lusduna and from 8.4 to 7.2% with Lantus.
V drugi študiji, ki je vključevala 531 bolnikov s sladkorno boleznijo tipa 2, je bilo povprečno zmanjšanje rezultata HbA1c z 8,3 na 7,2 % pri zdravilu Lusduna in z 8,4 na 7,2 % pri zdravilu Lantus.
The most common side effect with Lusduna (which may affect more than 1 in 10 people) is hypoglycaemia (low blood glucose).
Najpogostejši neželeni učinek zdravila Lusduna (ki se lahko pojavi pri več kot 1 bolniku od 10) je hipoglikemija (nizka raven glukoze v krvi).
What benefits of Lusduna have been shown in studies?
Kakšne koristi je zdravilo Lusduna izkazalo v študijah?
It contains the active substance insulin glargine.
Vsebuje zdravilno učinkovino insulin glargin.
Other information about Lusduna
Druge informacije o zdravilu Lusduna
Insulin glargine, the active substance in Lusduna, enters the bloodstream more slowly than human insulin after injection and so it works for longer.
Insulin glargin, zdravilna učinkovina v zdravilu Lusduna, po injiciranju vstopa v krvni obtok počasneje kot humani insulin, zato deluje dlje.
What is Lusduna and what is it used for?
Kaj je zdravilo Lusduna in za kaj se uporablja?
In the first supportive study, involving 506 patients with type 1 diabetes, the average HbA1c score was reduced from 8.0 to 7.4% with both Lusduna and Lantus.
V prvi podporni študiji, ki je vključevala 506 bolnikov s sladkorno boleznijo tipa 1, se je povprečni rezultat HbA1c pri zdravilu Lusduna in zdravilu Lantus zmanjšal z 8,0 na 7,4 %.
For more information about treatment with Lusduna, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Lusduna preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The dose of Lusduna is worked out for each patient and depends on the patient's blood glucose (sugar) level and treatment with other insulin medicines.
Odmerek zdravila Lusduna se prilagodi posameznemu bolniku in je odvisen od bolnikove ravni glukoze (sladkorja) v krvi in zdravljenja z drugimi insulinskimi zdravili.
The reference medicine for Lusduna is Lantus.
Referenčno zdravilo za zdravilo Lusduna je zdravilo Lantus.
For practical information about using Lusduna, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Lusduna naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The Committee recommended that Lusduna be given marketing authorisation.
Priporočil je, da se za zdravilo Lusduna izda dovoljenje za promet.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lusduna have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo tega zdravila upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
In both studies, the main measure of effectiveness was the change after 24 weeks of treatment in the level in the blood of glycosylated haemoglobin (HbA1c), a substance which indicates how well blood glucose is controlled.
V obeh študijah je bilo glavno merilo učinkovitosti sprememba ravni glikoziliranega hemoglobina (HbA1c) v krvi, snovi, ki označuje uspešnost uravnavanja glukoze v krvi, po 24 tednih zdravljenja.
What are the risks associated with Lusduna?
Kakšna tveganja so povezana z zdravilom Lusduna?
Lusduna is a replacement insulin that acts in the same way as the body's own insulin and helps glucose enter cells from the blood.
Zdravilo Lusduna je nadomestni insulin, ki deluje enako kot telesu lastni insulin in pomaga glukozi pri vstopanju iz krvi v celice.
Two additional studies showed that Lusduna is absorbed into the body and works on blood glucose in the same way as the reference medicine, Lantus.
Dve dodatni študiji sta pokazali, da se zdravilo Lusduna absorbira v telo in deluje na glukozo v krvi enako kot referenčno zdravilo Lantus.
For the full list of all side effects and restrictions with Lusduna, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Lusduna glejte navodilo za uporabo.
Lusduna is a ‘biosimilar medicine'.
Zdravilo Lusduna je „podobno biološko zdravilo“.
Lusduna insulin glargine
Lusduna insulin glargin
Why is Lusduna approved?
Zakaj je bilo zdravilo Lusduna odobreno?
Lusduna is available in pre-filled disposable pens and can only be obtained with a prescription.
Zdravilo Lusduna je na voljo v napolnjenih injekcijskih peresnikih za enkratno uporabo ter se predpisuje in izdaja le na recept.
Two supportive studies found that the effectiveness of once-daily Lusduna was comparable to Lantus.
V dveh podpornih študijah so ugotovili, da je učinkovitost zdravila Lusduna z enkrat dnevnim odmerjanjem primerljiva z učinkovitostjo zdravila Lantus.
It is not intended to provide practical advice on how to use Lusduna.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Extensive laboratory studies comparing Lusduna with Lantus have shown that insulin glargine in Lusduna is highly similar to that in Lantus in terms of chemical structure, purity and biological activity.
Obsežne laboratorijske študije, v katerih so zdravilo Lusduna primerjali z zdravilom Lantus, so pokazale, da je zdravilna učinkovina insulin glargin zdravila Lusduna po zgradbi, čistosti in biološkem delovanju zelo podobna zdravilni učinkovini zdravila Lantus.
How does Lusduna work?
Kako zdravilo Lusduna deluje?
How is Lusduna used?
Kako se zdravilo Lusduna uporablja?
Lusduna can also be used with diabetes medicines taken by mouth in patients who have type 2 diabetes.
Pri bolnikih s sladkorno boleznijo tipa 2 se zdravilo Lusduna lahko uporablja tudi s peroralnimi zdravili za zdravljenje sladkorne bolezni.
Further information on Talzenna can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/talzenna
Nadaljnje informacije o zdravilu Talzenna so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/talzenna
What measures are being taken to ensure the safe and effective use of Talzenna?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Talzenna?
The European Medicines Agency therefore decided that Talzenna's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Talzenna večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Women must not breastfeed during treatment with Talzenna and for a month after stopping treatment.
Ženske med zdravljenjem z zdravilom Talzenna in še en mesec po koncu zdravljenja ne smejo dojiti.
Talzenna can increase the time these patients live without their disease getting worse.
Zdravilo Talzenna lahko podaljša čas preživetja teh bolnikov brez poslabšanja bolezni.
As for all medicines, data on the use of Talzenna are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Talzenna stalno spremljajo.
Other information about Talzenna
Druge informacije o zdravilu Talzenna
What benefits of Talzenna have been shown in studies?
Kakšne koristi zdravila Talzenna so se pokazale v študijah?
The dose may be reduced or treatment interrupted if certain side effects develop.
Odmerek bo morda treba zmanjšati ali zdravljenje prekiniti, če se pojavijo določeni neželeni učinki.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Talzenna have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Talzenna upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What is Talzenna and what is it used for?
Kaj je zdravilo Talzenna in za kaj se uporablja?
An overview of Talzenna and why it is authorised in the EU
Pregled zdravila Talzenna in zakaj je odobreno v EU
Why is Talzenna authorised in the EU?
Zakaj je bilo zdravilo Talzenna odobreno v EU?
What are the risks associated with Talzenna?
Kakšna tveganja so povezana z zdravilom Talzenna?
For more information about using Talzenna, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Talzenna glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Therefore, when PARP proteins are blocked, the damaged DNA in cancer cells cannot be repaired, and as a result the cancer cells die.
Z zaviranjem beljakovin PARP se poškodovana DNK v rakavih celicah ne more popraviti, zato rakave celice odmrejo.
Side effects reported with Talzenna are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Talzenna, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
The side effects with Talzenna were generally well-tolerated and when needed, manageable with dose modifications, and/or standard supportive medical therapy.
Neželene učinke zdravila Talzenna so bolniki na splošno dobro prenašali, po potrebi pa so bili obvladljivi s spremembami odmerka in/ali standardnimi podpornimi medicinskimi terapijami.
The active substance in Talzenna, talazoparib, blocks the action of enzymes called human poly-ADP ribose polymerase (PARP), which are proteins that help to repair damaged DNA in cells (both in normal and in cancer cells) during cell division.
Učinkovina v zdravilu Talzenna, talazoparib, zavira delovanje encimov, imenovanih humane poli (ADPriboza) polimeraze (PARP), tj. beljakovin, ki v celicah (normalnih in rakavih) med celično delitvijo pomagajo popravljati poškodovano DNK.
Talzenna can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the use of cancer medicines.
Predpisovanje in izdaja zdravila Talzenna je le na recept, zdravljenje pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
Talzenna is a cancer medicine used on its own to treat a type of breast cancer (HER2-negative with BRCA mutations) that has spread beyond the original site, in patients who have been treated with certain medicines which have stopped working or when these medicines are not suitable.
Talzenna je zdravilo za zdravljenje raka, ki se samostojno uporablja za zdravljenje vrste raka dojke (HER2-negativnega raka dojke z mutacijami BRCA), ki se je razširil zunaj prvotnega mesta, pri bolnikih, ki so bili zdravljeni z določenimi zdravili, ki so prenehala delovati, ali kadar ta zdravila niso primerna.
The most common severe side effects (which may affect more than 1 in 10 people) which led to changes in the dose of Talzenna are anaemia, neutropenia and thrombocytopenia.
Najpogostejši resni neželeni učinki (ki se lahko pojavijo pri več kot 1 osebi od 10), zaradi katerih je bilo treba spremeniti odmerke zdravila Talzenna, so anemija, nevtropenija in trombocitopenija.
Talzenna was shown to be effective at increasing the time patients live without their disease getting worse in one main study involving 431 patients with HER2-negative breast cancer with BRCA mutations whose cancer had spread.
Zdravilo Talzenna se je izkazalo za učinkovito pri podaljšanju časa, ki ga bolniki preživijo brez poslabšanja bolezni, v eni glavni študiji, v katero je bilo vključenih 431 bolnikov s HER2-negativnim rakom dojke z mutacijami BRCA, pri katerih se je rak razširil.
The most common side effects with Talzenna (which may affect more than 1 in 4 people) are tiredness, anaemia (low red blood cell counts which can cause tiredness and pale skin), nausea (feeling sick), neutropenia (low levels of neutrophils, a type of white blood cell that fights infection), thrombocytopenia (low blood levels of platelets), and headache.
Najpogostejši neželeni učinki zdravila Talzenna (ki se lahko pojavijo pri več kot 1 osebi od 4) so utrujenost, anemija (nizko število rdečih krvnih celic, ki lahko povzroči utrujenost in bledo kožo), navzeja (siljenje na bruhanje), nevtropenija (nizke ravni nevtrofilcev, tj. vrste belih krvnih celic, ki se borijo proti okužbam), trombocitopenija (nizka raven trombocitov) in glavobol.
Talzenna is available as capsules (1 mg and 0.25 mg) and the recommended dose is 1 mg once a day.
Zdravilo Talzenna je na voljo v obliki kapsul (1 mg in 0,25 mg), priporočeni odmerek pa je 1 mg enkrat na dan. Zdravljenje je treba nadaljevati, dokler ima bolnik od njega korist, neželeni učinki pa so znosni.
Patients treated with Talzenna lived on average for 8.6 months without their disease getting worse compared with 5.6 months for patients treated with the doctor's choice of another cancer medicine.
so v povprečju živeli 8,6 meseca brez poslabšanja bolezni, bolniki, ki so prejemali drugo zdravilo za zdravljenje raka po zdravnikovi presoji, pa 5,6 meseca.
Talzenna contains the active substance talazoparib.
Zdravilo Talzenna vsebuje učinkovino talazoparib.
Generally the outcome is poor for patients with HER2-negative breast cancer with BRCA mutations whose cancer has spread.
Na splošno je za bolnike s HER2-negativnim rakom dojke z mutacijami BRCA, pri katerih rak se je razširil, izid slab.
For the full list of side effects and restrictions with Talzenna, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Talzenna glejte navodilo za uporabo.
How is Talzenna used?
Kako se zdravilo Talzenna uporablja?
How does Talzenna work?
Kako zdravilo Talzenna deluje?
Further information on Fasenra can be found on the Agency's website: ema.europa.eu/medicines/Human/EPAR/fasenra.
Nadaljnje informacije za zdravilo Fasenra so na voljo na spletni strani agencije: ema.europa.eu/medicines/Human/EPAR/fasenra.
Fasenra received a marketing authorisation valid throughout the EU on 8 January 2018.
Za zdravilo Fasenra je bilo 8. januarja 2018 izdano dovoljenje za promet, veljavno po vsej EU.
What measures are being taken to ensure the safe and effective use of Fasenra?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Fasenra?
The European Medicines Agency therefore decided that Fasenra's benefits are greater than its risks and recommended that it be approved for use in the EU.
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Fasenra večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
The recommended dose is 30 mg injected under the skin of the thighs or belly every 4 weeks for the first 3 doses, and every 8 weeks afterwards.
Priporočeni odmerek je 30 mg, injiciran v podkožje stegna ali trebuha vsake štiri tedne pri prvih treh odmerkih, nato pa vsakih osem tednov.
Fasenra should be given for as long as the patient benefits from it, and doctors should re-assess at least once a year whether treatment should be continued.
Zdravilo Fasenra je treba dajati, dokler bolniku koristi, zdravnik pa naj o nadaljevanju zdravljenja presodi vsaj enkrat letno.
As for all medicines, data on the use of Fasenra are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Fasenra stalno spremljajo.
Side effects reported with Fasenra are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Fasenra, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
What benefits of Fasenra have been shown in studies?
Kakšne koristi zdravila Fasenra so se pokazale v študijah?
This helps to reduce inflammation, resulting in a reduction in asthma attacks and improvement of symptoms.
S tem ublaži vnetje, kar zmanjša število napadov astme in izboljša simptome.
The medicine is well tolerated with few side effects.
Bolniki zdravilo dobro prenašajo in imajo malo neželenih učinkov.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fasenra have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Fasenra upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Why is Fasenra authorised in the EU?
Zakaj je bilo zdravilo Fasenra odobreno v EU?
An overview of Fasenra and why it is authorised in the EU
Pregled zdravila Fasenra in zakaj je odobreno v EU
For more information about using Fasenra, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Fasenra glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Other information about Fasenra
Druge informacije o zdravilu Fasenra
What are the risks associated with Fasenra?
Kakšna tveganja so povezana z zdravilom Fasenra?
What is Fasenra and what is it used for?
Kaj je zdravilo Fasenra in za kaj se uporablja?
If the injection is given by a doctor or carer, it can also be given under the skin of the upper arm.
Če zdravilo injicira zdravnik ali negovalec, se lahko injekcija daje tudi v podkožje nadlakti.
A third study involving 220 patients showed that more patients given Fasenra had their condition improved to the extent that they could reduce their dose of corticosteroids by an average of 75% compared with 25% of those given placebo.
Tretja študija, v katero je bilo vključenih 220 bolnikov, je pokazala, da je bil delež bolnikov, pri katerih se je stanje izboljšalo toliko, da so lahko zmanjšali odmerek kortikosteroidov, večji pri bolnikih, ki so prejemali zdravilo Fasenra, kot pri tistih, ki so prejemali placebo, in sicer 75 % v primerjavi s 25 %.